Analysis of the Efficacy and Mechanism of Action of Xuebijing Injection on ARDS Using Meta-Analysis and Network Pharmacology

Table 1

Demographic and clinical characteristics of the included studies.

Author, year	Random method	Sample size (I/C)	Male (I/C)	Age (years) (I/C)	Intervention	Control	Outcomes	Indications
Fang and Wang, 2013 [26]	Random number table	40/36	22/19		Xuebijing 100 mL iv q12h for 7 days	Conventional treatment	Mortality, ICU stay, IL-6, TNF-α,	ARDS
Liu et al., 2012	Random number table	91/81	68/57	55/53	Xuebijing 100 mL iv q12h for 7 days	Conventional treatment	Mortality, ICU stay	ARDS
Song et al., 2019 [27]	Random number	334/341	224/234		Xuebijing 100 mL iv q12h for 7 days	Placebo (saline 100 mL)	Mortality, ICU stay	SP
Chu, 2017 [28]	Draw lots	43/43	25/26		Xuebijing 100 mL iv q12h for 7 days	Low molecular weight heparin 5 U/kg/h)	Mortality, ICU stay, IL-6, TNF-α	ARDS
Gao et al., 2014 [29]	Random number	63/63	34/36		Xuebijing 100 mL iv bid for 7 days	Conventional treatment	ICU stay, IL-6, TNF-α	SP
Huang et al., 2008 [30]	Random number	36/36	20/22		Xuebijing 50 mL iv bid for 7 days	Conventional treatment	Mortality, IL-6, TNF-α	ARDS
Tian and Sun, 2012 [31]	Draw lots	50/50	57		Xuebijing 50 mL iv q12h for 7 days	Conventional treatment	Mortality, ICU stay, IL-6, TNF-α	ARDS
Liu et al., 2016 [32]	Random number table	30/30	17/16		Xuebijing 50 mL iv bid for 7 days	Conventional treatment	ICU stay, IL-6, TNF-α	ARDS
Wang, 2017 [33]	Random number table	48/48	26/25		Xuebijing 50 mL iv bid for 7 days	Conventional treatment	ICU stay, TNF-α	ARDS
Wang, 2019 [34]	NR	50/50	33/32		Xuebijing 50 mL iv bid for 7 days	Conventional treatment	Mortality, ICU stay, IL-6, TNF-α	ARDS
Chen et al., 2010 [35]	Random number table	31/30	14/16		Xuebijing 100 mL iv bid for 7 days	Conventional treatment	Mortality, ICU stay, IL-6	ARDS
Xu et al., 2014 [36]	NR	28/28	19/17		Xuebijing 50 mL iv bid for 7 days	Conventional treatment	ICU stay, IL-6, TNF-α	ARDS
Zhao et al., 2010 [37]	NR	20/20	24		Xuebijing 50 mL iv bid for 7 days	Conventional treatment	Mortality, ICU stay, IL-6, TNF-α	ARDS
Chen and Li, 2011 [38]	Random number table	30/30	33		Xuebijing 100 mL iv qd for 7 days	Conventional treatment	Mortality, IL-6, TNF-α	ARDS
Wang et al., 2011 [39]	NR	20/24	12/12		Xuebijing 100 mL iv bid for 7 days	Conventional treatment	Mortality, ICU stay	ARDS

Notes: I/C: intervention/control; NR: not reported; SP: severe pneumonia; ARDS: acute respiratory distress syndrome.